Non-small Cell Lung Cancer Metastasis Clinical Trials
Non-small Cell Lung Cancer Metastasis Clinical Trials are studies that work to extend the life span of advanced cancer patients. Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. While it makes up 80% to 85% of lung cancer patients, 60% of those are metastatic.
Metastasis refers to the spread of cancer cells to other organs, lymph nodes, or the brain. Metastatic cancer is considered as an advanced stage of cancer making treatment very difficult and usually with a 5-year survival rate at only 4.7%. Current treatments cannot fully cure cancer at this stage but rather focus on increasing patient life and quality. Non-small Cell Lung Cancer Metastasis Clinical Trials are aimed at finding alternatives to existing treatments and making progress against the disease.
What are Clinical Trials?
Medical professionals and researchers are always looking for new ways to provide better treatment for NSCLC patients. These scientific studies are conducted on volunteers and observations are made on the effect of these new methods on cancer cells. New drugs used for treatment are a result of these clinical trials and volunteers are the first to be treated with the newly produced drugs.
Non-small Cell Lung Cancer Metastasis Clinical Trials continues for all different phases of those studies. Usually patients who do not respond to the current treatment options, find clinical trials which may lead to better, safer and more effective treatment options.
In a clinical trial, along with positive outcomes, there may also be risks such as the side effects of the treatment. Before starting treatment, the patient is informed about all possible outcomes.
Phases of Clinical Trials
Clinical trials consist of 4 steps to ensure that the treatment works and not endanger human health.
These steps are;
- Phase I Clinical Trial: Researchers test the reliability of the new drug or therapy developed for humans. Medicines may have previously been tested on animals. At this stage, researchers collect information on topics such as dose adjustment, side effects, frequency of use, and the effect of the drug. It is usually done with about 10 to 30 volunteers.
- Phase II Clinical Trial: At this stage, researchers have the chance to observe the reliability, safety, and positive effect of the treatment. It also tests the specific areas that treatment affects. It examines tumor regression, blood values and body data.
- Phase III Clinical Trial: If positive results are observed in Stage 2, then Stage 3 is passed. At this stage, the newly developed treatment is compared with the existing treatments and is the required phase to lead to approval for commercial use. The effect on the disease and its side effects are compared.
- Phase IV Clinical Trial: Once the drug is approved, researchers continue to look for the effect of treatment with different doses used in real world because the drug is commercially available.
Deciding to Join a Clinical Trial
NSCLC patients may have several different reasons to participate in clinical trials. First of all, current treatments do not provide complete solutions for advanced cancer patients. It is intended to slow down the disease and suppress side effects. Clinical research provides hope for advanced NSCLC patients.
Others volunteer for clinical trials to make progress in fighting this disease. They may want to contribute to the treatment of both their own illnesses and future NSCLC patients.
Non-small Cell Lung Cancer Metastasis Clinical Trials Patient Safety
Clinical trials carry some risks since they are not fully approved and have not been widely used. These risks may include side effects of new drugs or a risk to overall health.
NSCLC patients should be informed, in detail, about these risks. Before any trial begins, the medicine to be used against the disease and how it will affect the disease is explained. The patient is always informed about the side effects and all risks that may arise from the treatment. In addition, the patient should be informed about all tests, sessions and examinations during the treatment process.
Some Non-small Cell Lung Cancer Metastasis Clinical Trials are focused in new molecules targeting NSCLC biomarkers, such as EGFR, ROS, ALK, MET, BRAF, MET, RET, KRAS and others.
Massive Bio allows you to come together with clinics and researchers who research your disease. For more information about non-small cell lung cancer metastasis clinical trials, you can contact Massive Bio.